Genmab (Danish) invents antibody cancer drugs, earning royalties on Darzalex.
Genmab A/S (GMAB) is expected to report earnings on Thursday, November 5, 2026, before the open. Estimated release time before open. Consensus EPS estimate is $0.37.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | Jun 2026 qtr | $0.37 | $0.49 | — | $1.16B |
| 2026-05-07 | Mar 2026 qtr | $0.15 | $0.09 | — | $899.32M |
| 2026-02-17 | Dec 2025 qtr | $0.46 | $0.05 | — | $1.05B |
| 2025-08-07 | Jun 2025 qtr | $0.39 | $0.54 | — | $924.81M |
| 2025-05-08 | Mar 2025 qtr | $0.23 | $0.04 | — | $105.23M |
| 2025-11-06 | Dec 2024 qtr | $0.48 | $0.65 | — | $1.02B |
| 2024-08-08 | Jun 2024 qtr | $0.29 | $0.32 | +10.3% | $779.00M |
| 2023-11-07 | Sep 2023 qtr | $3.14 | $3.26 | +3.8% | — |
GMAB has beaten consensus EPS in 2 of its last 2 scored quarters.
See GMAB on the live calendar →